Instilling Public Trust in COVID Vaccine Allocation Plan: Gov’t Hopes Outside Scientists Will Help
National Academy of Medicines is developing a framework for equitable COVID-19 vaccine distribution which, CDC and NIH hope, will help shore up public trust ahead of the unenviable task of having to decide who should be the first to get limited vaccine resources. CDC Director Robert Redfield said the distribution strategy should help lessen the health disparities seen with COVID-19 infections.
You may also be interested in...
COVID Vaccine Distribution Plan From National Academies Leaves Room For Adjustments Based On Trial Results
Draft allocation framework expects health care workers would take up much of the initial vaccine supply and suggests the elderly and people with two comorbid conditions receive vaccination next. NAM suggests states get a population-based allotment, leaving local officials to make many of the tough decisions under the framework, which could be adjusted based on clinical trial data.
The massive need for a COVID-19 vaccine and treatments has heightened the biopharmaceutical industry’s visibility among consumers and the world’s largest biopharma companies are getting a boost in positive perception this year, according to a new FutureBrand survey. If sustained, this could have dividends in areas such as attracting industry talent and clinical trial participants. But much remains to be seen as biopharma navigates the final stretch of clinical development, regulatory review, distribution and patient access.
The previous administration’s forethought may have given the Trump team a leg up in vaccine distribution. McKesson’s experience as a central distributor for the Vaccines for Children’s program, H1N1 and its role in seasonal flu vaccine distribution should make it well positioned to handle the COVID-19 effort in the US, experts said.